Article (Scientific journals)
Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism
Palacios, S.; Foidart, Jean-Michel; Genazzani, A. R.
2006In Maturitas, 55 (4), p. 297-307
Peer Reviewed verified by ORBi
 

Files


Full Text
Palacios S M 2006.pdf
Author postprint (385.88 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
progestogen; hormone replacement therapy; drospirenone; post-menopausal women; hypertension
Abstract :
[en] Unlike other currently available progestogens, drospirenone (DRSP) has a pharmacological profile, which closely mimics that of endogenous progesterone, most notably potent anti-aldosterone and anti-androgenic effects. Consequently, DRSP, when combined with 17 beta-estradiol (E2) as hormone replacement therapy (HRT), offsets E2-related water and sodium retention by blocking the mineralocorticoid receptor. This review evaluates the potential benefits offered by DRSP as the progestin component of HRT with respect to its anti-aldosterone activity, which translates into positive effects on body weight and blood pressure in clinical trials of continuous, combined E2/DRSP in post-menopausal women. In a 1-year, large-scale, randomised, controlled trial, E2 1 mg/DRSP 2 mg significantly decreased mean body weight by 1.2 kg versus baseline (P < 0.001), whereas patients receiving E2 1 mg gained weight. E2 1 mg/DRSP 2 mg also significantly lowered mean systolic blood pressure (SBP) by 9.0 mmHg from baseline (P < 0.05) versus 3.7 mmHg in the E2 1 mg group (P = 0.220) in a sub-group of hypertensive women. In addition, E2/DRSP was not associated with hyperkalaemia (potassium >= 5.5 meq/L) irrespective of concomitant use of ACE inhibitors, angiotensin II receptor antagonists or non-steroidal anti-inflammatory drugs, and co-morbid diabetes mellitus. In summary, as well as effectively treating climacteric symptoms, DRSP 2 mg combined with E2 I mg has shown positive effects on body weight and blood pressure in clinical trials, most likely due to DRSP's anti-aldosterone properties. This combination may therefore offer an alternative therapeutic option with additional benefits beyond current HRT agents for symptomatic post-menopausal women. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
Disciplines :
Geriatrics
Sociology & social sciences
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Palacios, S.
Foidart, Jean-Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Genazzani, A. R.
Language :
English
Title :
Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism
Publication date :
20 November 2006
Journal title :
Maturitas
ISSN :
0378-5122
eISSN :
1873-4111
Publisher :
Elsevier North Holland Biomedical Press, Limerick, Ireland
Volume :
55
Issue :
4
Pages :
297-307
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 March 2009

Statistics


Number of views
460 (2 by ULiège)
Number of downloads
718 (1 by ULiège)

Scopus citations®
 
38
Scopus citations®
without self-citations
36
OpenCitations
 
28

Bibliography


Similar publications



Contact ORBi